Lobbying disclosures · Lobbying report
PFE: third_quarter 2026 lobbying report
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Pl
Follow PFE- Became public
- Oct 20, 2026, 2:54 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 5:38 PM EST
Why this is connected
Exact legal-name match: PFIZER INC (https://www.sec.gov/Archives/edgar/data/78003/).
Reported lobbying amounts
Expenses: $3,600,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/cb8d32e9-83d7-48be-b71a-d96e2736dd8d/","filing_uuid":"cb8d32e9-83d7-48be-b71a-d96e2736dd8d","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/cb8d32e9-83d7-48be-b71a-d96e2736dd8d/print/","filing_document_content_type":"text/html","income":null,"expenses":"3600000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Skelton","dt_posted":"2026-10-20T14:54:17-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1275 Pennsylvania Avenue, NW","registrant_address_2":"Suite 501","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":31326,"url":"https://lda.gov/api/v1/registrants/31326/","house_registrant_id":31354,"name":"PFIZER INC.","description":"Biopharmaceuticals","address_1":"1275 Pennsylvania Avenue, NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-08-21T13:00:31.079287-04:00"},"client":{"id":138225,"url":"https://lda.gov/api/v1/clients/138225/","client_id":12,"name":"PFIZER INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-02-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":106110,"prefix":null,"prefix_display":null,"first_name":"FRANCISCO","nickname":null,"middle_name":null,"last_name":"CARRILLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":106110,"prefix":null,"prefix_display":null,"first_name":"FRANCISCO","nickname":null,"middle_name":null,"last_name":"CARRILLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72512,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":null,"last_name":"CLAEYS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68817,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":null,"last_name":"MUELLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69774,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":null,"last_name":"ROBINSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":106111,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"STROIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138233,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"SWENSON","last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143695,"prefix":"mrs","prefix_display":"MRS.","first_name":"ANGELA","nickname":null,"middle_name":"BOOTHE","last_name":"WILES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in PFE
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 25, 2026 · disclosed Oct 7, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 11, 2026 · disclosed Oct 7, 2026 · Dependent
- Oct 7, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
$1K–$15K · Traded Nov 26, 2024 · disclosed Aug 7, 2026 · filed 619 days later
Got $3K from the company’s PAC - Jul 21, 2026$50K–$100K
Sen. Alan Armstrong (R-OK)
$50K–$100K · Traded Mar 24, 2026 · disclosed Jul 21, 2026 · filed 119 days later
Committee overlap: HELP - Jul 16, 2026$15K–$50K
Sen. Tommy Tuberville (R-AL)
$15K–$50K · Traded Jun 8, 2026 · disclosed Jul 16, 2026 · Joint
Committee overlap: HELP - May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.